![中国首款自研P-CAB替戈拉生片获批 罗欣药业“创仿结合”战略迎新里程碑](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![重磅信号!四环医美+生物医药双轮驱动战略迈出坚实步伐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
01
02
![重磅信号!四环医美+生物医药双轮驱动战略迈出坚实步伐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
03
4.《大事件!四环医药拟分拆剥离仿制药业务,估值逻辑即将发生蜕变》瞪羚社 2022.7.18
5.《四环医药-公司点评:医美+生物制药双轮驱动,前瞻布局成就华丽转型》2021.09.05
![重磅信号!四环医美+生物医药双轮驱动战略迈出坚实步伐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
推荐阅读
![重磅信号!四环医美+生物医药双轮驱动战略迈出坚实步伐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
![重磅信号!四环医美+生物医药双轮驱动战略迈出坚实步伐](https://www.drugtimes.cn/wp-content/themes/justnews/themer/assets/images/lazy.png)
本篇文章来源于微信公众号:药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权
01
02
03
推荐阅读
本篇文章来源于微信公众号:药时代
发布者:haitao.zhao,转载请首先联系contact@drugtimes.cn获得授权